Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23208040 | 0.82 | MAPT (0.46) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL8032979 | 0.77 | XDH (0.54) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL3277882 | 0.77 | XDH (0.50) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL23207495 | 0.77 | XDH (0.50) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL28082044 | 0.76 | XDH (0.51) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL1590095 | 0.76 | FAAH (0.55) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL12545534 | 0.75 | XDH (0.50) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL17951858 | 0.75 | FAAH (0.54) | XDHFAAHMAPTKDM4ERAB9A | |
| SCHEMBL250149 | 0.74 | XDH (0.52) | XDHFAAHMAPTKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL23320558 | 0.74 | FAAH (0.54) | XDHFAAHMAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | claimed |
| CN-101987847-A | Novel heterocyclic NF-kB inhibitors | 4SC AG | 2011-03-23 | — | — | CN | claimed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | claimed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | claimed |
| EP-1797084-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006032322-A1 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2006-03-30 | — | — | WO | claimed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | claimed |
| CN-101987847-B | Novel heterocyclic NF-kB inhibitors | 4SC AG | 2012-10-10 | — | — | CN | disclosed |
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2343293-A1 | NOVEL PIPERIDIN-4-YL-THIAZOLE-CARBOXAMIDE ANALOGUES AS INHIBITORS OF T-CELL PROLIFERATION AND USES THEREOF | 4SC AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| CN-101987847-A | Novel heterocyclic NF-kB inhibitors | 4SC AG | 2011-03-23 | — | — | CN | disclosed |
| US-20110052532-A1 | Pharmaceutical composition comprising a cytokine | STROBL STEFAN | 2011-03-03 | — | — | US | disclosed |
| EP-1912982-A2 | NOVEL HETEROCYCLIC NF- B INHIBITORS | 4SC AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007104557-A2 | NOVEL HETEROCYCLIC NF-KB INHIBITORS | 4SC AG (DE) | 2007-09-20 | — | — | WO | disclosed |
| EP-1797084-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007016979-A2 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006032322-A1 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052532-A1 | Pharmaceutical composition comprising a cytokine | IL2, IL17A, IFNG | XDH 2113/4885FAAH 1248/4885MAPT 2853/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | XDH 2985/4885FAAH 1424/4885MAPT 4665/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | XDH 2843/4885FAAH 2167/4885MAPT 4818/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | XDH 2623/4885FAAH 2191/4885MAPT 4540/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | XDH 3092/4885FAAH 2181/4885MAPT 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.